XML 62 R51.htm IDEA: XBRL DOCUMENT
v3.24.3

Equity Investments (Details) |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Aug. 15, 2024 USD ($) | Feb. 07, 2023 $ / shares shares | Apr. 30, 2024 USD ($) shares | Apr. 30, 2022 USD ($) shares | Jul. 31, 2021 USD ($) shares | May 31, 2021 USD ($) shares | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2023 USD ($)
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Realized gain |  |  |  |  |  |  | $ 25,459,000 | $ (14,522,000) | $ 27,763,000 | $ 61,869,000 |
Nimbus Therapeutics, LLC |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity security |  |  |  |  |  |  | 1,928,000 |  | 1,928,000 |  | $ 1,928,000
Unrealized gain (loss) |  |  |  |  |  |  | 0 | 2,165,000 | 0 | 2,165,000 |
Realized gain |  |  |  |  |  |  |  |  |  | 147,322,000 |
Morphic Holding, Inc. |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from disposal of shares | $ 47,588,000 |  |  |  |  |  |  |  |  |  |
Mark-to-market gain (loss) |  |  |  |  |  |  | 19,140,000 | (28,740,000) | 23,474,000 | (3,206,000) |
Marketable securities |  |  |  |  |  |  | 0 |  | 0 |  | 24,114,000
Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity security |  |  |  |  |  |  | 4,700,000 |  | 4,700,000 |  | 1,700,000
Structure Therapeutics |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Mark-to-market gain (loss) |  |  |  |  |  |  | 6,318,000 | $ 12,052,000 | 4,289,000 | $ 62,910,000 |
Marketable securities |  |  |  |  |  |  | $ 58,588,000 |  | $ 58,588,000 |  | $ 55,509,000
Series B Preferred Stock | Structure Therapeutics |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Conversion ratio |  | 1 |  |  |  |  |  |  |  |  |
Series B Preferred Stock | Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of preferred shares purchased (in shares) | shares |  |  |  |  |  | 631,377 |  |  |  |  |
Cash payments to purchase of shares |  |  |  |  |  | $ 1,700,000 |  |  |  |  |
Series B Preferred Stock | Structure Therapeutics |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of preferred shares purchased (in shares) | shares |  |  |  | 148,210 | 494,035 |  |  |  |  |  |
Cash payments to purchase of shares |  |  |  | $ 600,000 | $ 2,000,000 |  |  |  |  |  |
Series C Preferred Stock | Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of preferred shares purchased (in shares) | shares |  |  | 1,416,450 |  |  |  |  |  |  |  |
Cash payments to purchase of shares |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
ADR | Structure Therapeutics |  |  |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of shares purchased (in shares) | shares |  | 275,000 |  |  |  |  |  |  |  |  |
Purchase price (in USD per share) | $ / shares |  | $ 15.00 |  |  |  |  |  |  |  |  |
Stock split, conversion ratio |  | 3 |  |  |  |  |  |  |  |  |

X
- Definition American Depository Shares Purchased, Price Per Share + References No definition available. + Details
Name: | sdgr_AmericanDepositorySharesPurchasedPricePerShare
Namespace Prefix: | sdgr_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of preferred shares purchased. + References No definition available. + Details
Name: | sdgr_NumberOfPreferredSharesPurchased
Namespace Prefix: | sdgr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Shares Purchased + References No definition available. + Details
Name: | sdgr_NumberOfSharesPurchased
Namespace Prefix: | sdgr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiRealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion for each share of preferred stock to be converted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details
Name: | us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_NimbusTherapeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_MorphicHoldingIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_AjaxTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_StructureTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sdgr_StructureTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=dei_AdrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |